OrganismosDoençasCompostos Químicos e DrogasTécnicas e Equipamentos Analíticos, Diagnósticos e TerapêuticosDisciplinas e OcupaçõesAntropologia, Educação, Sociologia e Fenômenos SociaisCiência da InformaçãoDenominações de GruposAssistência SaúdeDenominações Geográficas
FarmacovigilânciaSistemas de Notificação de Reações Adversas a MedicamentosVigilância de Produtos ComercializadosEfeitos Colaterais e Reações Adversas Relacionados a MedicamentosFarmacoepidemiologiaProcedimentos de Readequação SexualMonitoramento de MedicamentosMineração de DadosCentros de Controle de IntoxicaçõesUnited States Food and Drug AdministrationArtemisininasBases de Dados FactuaisEnfermeiras ObstétricasGestão de RiscosAntimaláricosFrançaCentros de Atenção TerciáriaOrganização do FinanciamentoPlasmodiumMaláriaPreparações Farmacêuticas

Pharmacovigilance of herbal medicine. (25/105)

 (+info)

Development and delivery of clinical pharmacology in regulatory agencies. (26/105)

 (+info)

Pharmacovigilance. (27/105)

 (+info)

Pharmacovigilance practice and risk control of Traditional Chinese Medicine drugs in China: current status and future perspective. (28/105)

 (+info)

Spontaneously reported hepatic adverse drug events in Korea: multicenter study. (29/105)

 (+info)

Traditional Chinese medicine research in the post-genomic era: good practice, priorities, challenges and opportunities. (30/105)

 (+info)

Serum prolactin levels and the acute-phase efficacy in drug-naive schizophrenia treated with ziprasidone and olanzapine (translated version). (31/105)

OBJECTIVES. To study the efficacy and associated serum prolactin levels of ziprasidone and olanzapine treatment in drug-naive schizophrenia patients. METHODS. All 78 inpatients with drug-naive schizophrenia were recruited from the Department of Psychology, The Third Affiliated Hospital of Sun Yat-sen University. They were divided into either olanzapine group (n = 49 [24 men, 25 women]; mean [standard deviation] age, 24 [6] years) or ziprasidone group (n = 29 [14 men, 15 women]; mean [standard deviation] age, 23 [7] years), all of whom were treated for 4 weeks. The serum prolactin level, the Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression-Severity (CGI-S), and Clinical Global Impression-Improvement scores were measured before and at the end of treatment. RESULTS. In the olanzapine group, the respective mean (standard deviation) PANSS and CGI-S scores after the treatment (62 +/- 15 and 3 +/- 1) were significantly lower than those before the treatment (104 +/- 14 and 6 +/- 1) [p < 0.01]. In the ziprasidone group, the corresponding scores after the treatment (75 +/- 20 and 4 +/- 1) were also significantly lower than those before the treatment (104 +/- 17 and 6 +/- 1) [p < 0.01]. The decreases in mean (standard deviation) PANSS total (42 +/- 17) and PANSS positive scores (12 +/- 6) in the olanzapine group were significantly higher than those in the ziprasidone group (29 +/- 12 and 6 +/- 4, respectively) [p < 0.01]. The increase of serum prolactin in the ziprasidone female group (47 +/- 51 microg/L) was significantly higher than that in the ziprasidone male group (17 +/- 11 microg/L), the olanzapine male group (5 +/- 16 microg/L), and the olanzapine female group (21 +/- 34 microg/L) [p < 0.05]. CONCLUSIONS. Both ziprasidone and olanzapine are effective for treating drug-naive acute schizophrenia, but olanzapine was superior to ziprasidone in terms of positive and general psychopathological symptoms. In women, ziprasidone was associated with greater changes in prolactin level than olanzapine.  (+info)

Designing adverse event forms for real-world reporting: participatory research in Uganda. (32/105)

 (+info)